Capricor Therapeutics EVP Krasney Sells $752k Capricor EVP Michael Krasney sold $752,000 of CAPR stock (reported Apr 2, 2026); the filing warrants follow-up on whether this was a 10b5-1 plan or routine liquidity.

Capricor Therapeutics EVP Krasney Sells $752k: Capricor EVP Michael Krasney sold $752,000 of CAPR stock (reported Apr 2, 2026); the filing warrants follow-up on whether this was a 10b5-1 plan or routine… 👈 Read full analysis #CapricorTherapeutics #InsiderTrading #StockMarket #FinanceNews #Investing

Capricor Therapeutics Director Sells $3.5m in Shares Capricor director divested $3.5m of CAPR stock (Form 4 filed Apr 1, 2026; Investing.com Apr 2, 2026). Fazen analysis shows a 15% YoY rise in small‑cap biotech insider sell‑value in Q1 2026.

Capricor Therapeutics Director Sells $3.5m in Shares: Capricor director divested $3.5m of CAPR stock (Form 4 filed Apr 1, 2026; Investing.com Apr 2, 2026). Fazen analysis shows a 15% YoY rise in small‑cap… 👈 Read full analysis #CapricorTherapeutics #Biotech #InsiderSelling #StockMarket #Investing

Press Release

Shares declined after the FDA raised concerns during the review of #CapricorTherapeutics ( #CAPR) cell therapy candidate, deramiocel. The company is evaluating next steps.
prismmarketview.com/press-releas...

PRISM Mid-Day Movers: FDA Progress and Global Health Approvals Boost Indices
#CapricorTherapeutics Rises 18% on FDA Progress for Duchenne Cell Therapy
#TrinityBiotech Surges 20% Following WHO Approval for HIV Test Manufacturing Shift
prismmarketview.com/prism-mid-da...

Capricor Therapeutics stock falls after FDA inspection of manufacturing facility Investing.com -- Capricor Therapeutics Inc (NASDAQ:CAPR) stock tumbled 10.5% after the company announced that the FDA’s inspection of its San Diego manufacturing facility resulted in a Form 483 with several observations. The biotechnology company, which is developing cell and exosome-based therapeutics for rare diseases, said it has submitted responses to the FDA regarding the observations from the Pre-License Inspection (PLI) of its facility for Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). According to Capricor, the observations were primarily related to routine quality systems and documentation practices, with none requiring material changes to the cGMP process or facility. Despite the stock drop, CEO Linda Marbán characterized the inspection as "a major regulatory milestone" and expressed confidence that the facility will meet requirements to support product licensure and potential commercial launch. The company also announced that the FDA has scheduled an Advisory Committee meeting for July 30, 2025, though this date is pending confirmation. Capricor’s Biologics License Application (BLA) for Deramiocel remains under priority review with a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025. The company noted that at the mid-cycle review, no significant issues or major deficiencies were identified, and a late-cycle meeting is planned for mid-July 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #CapricorTherapeutics #BioTech #Investing #FDA #WallStreet